详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

miR-22 Suppresses EMT by Mediating Metabolic Reprogramming in Colorectal Cancer through Targeting MYC-Associated Factor X

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]The Second Department of General Surgery, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China. [2]Institute of Hepatobiliary, Pancreatic and Intestinal Disease, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China. [3]West China Hospital, Sichuan University-Ying Shan Hospital, Nanchong, 637000 Sichuan, China. [4]The Pain Department, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China.

出处：

DOI：

ISSN：

摘要：

Colorectal cancer (CRC) is one of the most frequent gastrointestinal cancers. MicroRNAs (miRNAs) have been proved to be unusually expressed in CRC progression and thus alter multiple pathological processes in CRC cells. However, the specific roles and mechanisms of miR-22 in CRC have not been clearly reported. MicroRNA-22 (miR-22) and MYC-associated factor X (MAX) expressions were determined by RT-qPCR in CRC tissues and cells. The targeted regulatory effects of miR-22 and MAX were confirmed by luciferase reporter and coimmunoprecipitation assays. Also, gain- and loss-of-function and rescue experiments were used to elucidate the function and mechanism of miR-22 and MAX in CRC cells and the mouse xenograft model. We discovered that miR-22 was hypermethylated and downregulated, while MAX was upregulated in CRC. miR-22 markedly inhibited migration, invasion, glycolysis, and cancer stem cell transcription factors in CRC cells. In addition, it was found that miR-22 can directly target MAX. Additional functional experiments confirmed that MAX overexpression can rescue the effects of miR-22 on the behavior of CRC cells. This study suggested that miR-22, as a cancer suppressor, participates in CRC progression by targeting MAX, which might provide basic information for therapeutic targets for CRC.Copyright © 2022 Shusen Xia et al.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 4 区医学

小类 | 3 区病理学 3 区生物工程与应用微生物 4 区遗传学 4 区医学：研究与实验

最新[2023]版：

无

第一作者：

第一作者机构： [1]The Second Department of General Surgery, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China. [2]Institute of Hepatobiliary, Pancreatic and Intestinal Disease, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China. [3]West China Hospital, Sichuan University-Ying Shan Hospital, Nanchong, 637000 Sichuan, China.

通讯作者：

通讯机构： [1]The Second Department of General Surgery, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China. [2]Institute of Hepatobiliary, Pancreatic and Intestinal Disease, The Affiliated Hospital of the North Sichuan Medical College, Nanchong, 637000 Sichuan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：